Regulation of PD-1 in T cells for cancer immunotherapy
- Resource Type
- Authors
- Yangqiu Li; Xibao Yu; Chengwu Zeng; Rili Gao
- Source
- European journal of pharmacology. 881
- Subject
- 0301 basic medicine
Transcription, Genetic
medicine.medical_treatment
T cell
T-Lymphocytes
Programmed Cell Death 1 Receptor
Epigenesis, Genetic
03 medical and health sciences
0302 clinical medicine
Immune system
Lymphocytes, Tumor-Infiltrating
Cancer immunotherapy
PD-L1
Neoplasms
medicine
Tumor Microenvironment
Animals
Humans
Receptor
Immune Checkpoint Inhibitors
Pharmacology
biology
Chemistry
Cancer
Immunotherapy
medicine.disease
Gene Expression Regulation, Neoplastic
030104 developmental biology
medicine.anatomical_structure
Cancer cell
biology.protein
Cancer research
Tumor Escape
030217 neurology & neurosurgery
Signal Transduction
- Language
- ISSN
- 1879-0712
Study of the molecular mechanisms underlying cancer immune escape is one of the core issues in immuno-oncology research. Cancer cells can evade T cell cytotoxicity by exploiting the upregulation of T cell inhibitory receptors on T cells and their ligands on cancer cells. These upregulated proteins include the inhibitory receptor programmed cell-death protein 1 (PD-1) and its ligand programmed cell death 1 ligand 1 (PD-L1), which can induce T cell exhaustion and reduce T cell activation. Characterizing PD-1 regulation will help to elucidate the molecular mechanisms underlying T cell exhaustion and improve cancer treatment. Recent studies have found that tumor cells regulate PD-1 during gene transcription, post-transcriptional regulation, and post-translational modification and influence the effects of the anticancer immune response by targeting PD-1. In this review,we summarize the mechanisms of PD-1 regulation in T cells.